Dietary Zinc
Zinc is the second most abundant trace element in the human body (~2–3 g total), with no dedicated labile storage form — making dietary adequacy critical. Absorbed via ZIP4 (SLC39A4) in duodenum/jejunum; bioavailability is strongly inhibited by phytates (IP6) in plant foods (PZR >15 → severe inhibition). Zinc functions in three biochemical roles: catalytic (carbonic anhydrase, carboxypeptidase, MMPs, ACE), structural (C₂H₂ zinc fingers — ~3% of human proteome), and regulatory (synaptic zinc, immune signalling). Key immune roles: thymulin (zinc-dependent thymic peptide driving T-cell maturation), NK cell cytotoxicity, macrophage respiratory burst. AREDS (n=3,640): zinc 80 mg/day → RR 0.72 for advanced AMD progression over 10 years.
Overview
Zinc (Zn, atomic number 30) is an essential trace mineral present in every cell of the human body. It ranks second only to iron as the most abundant trace element in humans, with a total body content of approximately 2–3 g distributed across muscle (~57%), bone (~29%), skin and hair (~6%), liver (~5%), and all other tissues. Notably high concentrations occur in the prostate gland, choroid of the eye, and immune cells. Unlike iron, zinc has no dedicated storage form — the body maintains no appreciable labile zinc reserve — making dietary adequacy critical for moment-to-moment immune function and enzyme activity.
Zinc bioavailability differs dramatically by dietary matrix. From animal foods (meat, shellfish), ~25–30% of dietary zinc is absorbed because cysteine-rich peptides from meat digestion form soluble zinc-amino acid chelates that maintain zinc solubility through the upper intestine. From plant foods, absorption falls to ~15–20% because phytic acid (inositol hexaphosphate, IP6) — the primary phosphate-storage form in plant seeds (legumes, grains, nuts) — binds zinc with high affinity in the GI lumen, forming insoluble zinc-phytate complexes. The molar phytate:zinc ratio (PZR) predicts bioavailability: PZR <5 (minimal inhibition), 5–15 (moderate), >15 (severe — common in un-fermented whole-grain and legume-staple diets). Fermentation (sourdough, tempeh, natto), soaking, and sprouting reduce phytate 25–75% via phytase activation, substantially improving zinc bioavailability.
Zinc functions in three distinct biochemical categories: catalytic (Zn²⁺ as Lewis acid in enzyme active sites), structural (tetrahedral Zn²⁺ coordination in zinc finger domains of transcription factors), and regulatory (synaptic zinc release from glutamatergic vesicles; zinc transients in immune signalling). The Global Burden of Disease estimates zinc deficiency as the fifth leading cause of disease burden in developing countries, manifesting primarily as childhood growth failure, immune deficiency, and increased mortality from diarrhoeal and respiratory infections.
Mechanism of Action
Intestinal Absorption: ZIP4 and Metallothionein
Dietary zinc (Zn2+) in duodenum / proximal jejunum
|
| ZIP4 (SLC39A4) -- apical brush-border importer (upregulated in deficiency)
| ZIP5 (SLC39A5) -- basolateral (efflux during zinc repletion)
v
Enterocyte cytoplasm
|
|-- Metallothionein (MT-1/MT-2): 7 Zn2+/molecule; induced by MTF1
| (High zinc -> more MT -> zinc trapped -> shed at villus tip -> limits absorption)
|-- ZnT5 (SLC30A5): ER/Golgi zinc loading of secretory zinc proteins
v
ZnT1 (SLC30A1) -- basolateral export into portal circulation
|
v Albumin (~80%) + alpha2-macroglobulin (~18%) -> liver -> systemic distribution
Zinc in 3 biochemical roles:
┌─────────────────────────────────────────────────────────┐
│ CATALYTIC (>300 enzymes): │
│ Carbonic anhydrase II: CO2 + H2O -> HCO3- + H+ (10^6/s)│
│ Carboxypeptidase A: C-terminal peptide digestion │
│ Alcohol dehydrogenase: ethanol -> acetaldehyde │
│ MMPs: ECM remodelling (wound healing, invasion) │
│ ACE: Ang I -> Ang II (target of ACE inhibitors) │
├─────────────────────────────────────────────────────────┤
│ STRUCTURAL (zinc fingers, ~3% human proteome): │
│ C2H2 type: Zn2+ tetrahedral (2Cys + 2His) │
│ GATA-3 (Th2), T-bet (Th1), RORgammat (Th17), │
│ Foxp3 (Treg), Runx2 (osteoblast), Sp7/Osterix │
│ RING domains (E3 ubiquitin ligases), PHD fingers │
├─────────────────────────────────────────────────────────┤
│ REGULATORY: │
│ Synaptic zinc (~300 uM from glutamatergic vesicles): │
│ -> NMDA-R modulation, GABA-A receptor, ASIC channels │
│ Immune zinc transients: │
│ -> BCR/TCR activation -> rapid Zn2+ flux │
│ -> modulates MAPK and PI3K/Akt signalling │
└─────────────────────────────────────────────────────────┘
Immune Function: Thymulin and Lymphocyte Biology
- Thymulin (FTS): Nonapeptide hormone secreted by thymic epithelial cells; active only when chelated with Zn²⁺. Apothymulin (zinc-free) is inactive. Drives thymocyte maturation → CD3⁺ T-cell development, CD4/CD8 differentiation, IL-2 receptor expression.
- T-helper cell transcription factors: GATA-3 (Th2), T-bet (Th1), RORγt (Th17), and Foxp3 (Treg) all contain zinc finger DNA-binding domains requiring Zn²⁺ for structural integrity. Deficiency → impaired T-cell lineage commitment.
- NK cell cytotoxicity: Perforin assembly and granzyme B activation in cytotoxic granules require zinc. Deficiency → ↓NK cell numbers and ADCC activity.
- Macrophage respiratory burst: NADPH oxidase-dependent superoxide generation against phagocytosed pathogens requires zinc. Deficiency → ↓phagocytic capacity, ↓IL-12 → biases away from Th1 protective immunity.
- Anti-inflammatory at adequate levels: Zinc upregulates A20/TNFAIP3 → NF-κB inhibition → ↓pro-inflammatory cytokines. This physiological anti-inflammatory effect contrasts with the immune-deficiency seen in frank zinc deficiency.
Pleiotropic Roles
Wound Healing
Zinc-dependent MMPs remodel ECM during granulation tissue formation. Keratinocyte proliferation and migration require zinc for collagen synthesis (prolyl hydroxylase) and keratin structure. Zinc-finger TF Runx2 governs osteoblastogenesis; deficiency → impaired fracture healing.
Retinal Function
Retinal pigment epithelium and choroid have the highest zinc concentration in the eye. Zinc is required for retinol dehydrogenase (retinol ↔ retinaldehyde) in the visual cycle; deficiency → night blindness (impaired dark adaptation). AREDS: 80 mg/day Zn → significant protection against advanced AMD.
CO₂ Transport (Carbonic Anhydrase)
Carbonic anhydrase II in RBCs contains catalytic Zn²⁺; converts CO₂ + H₂O ⇌ HCO₃⁻ + H⁺ at ~10⁶ reactions/sec — one of the fastest enzymes known. Essential for efficient CO₂ transport from tissues to lungs.
Oropharyngeal Antiviral (Common Cold)
Zn²⁺ ions released from lozenges directly inhibit rhinovirus 3C protease (Cys-protease; Zn²⁺ coordinates active-site Cys) and block rhinovirus attachment to ICAM-1. Requires slow lozenge dissolution in mouth; swallowed tablets ineffective for cold treatment.
Dietary Sources & RDA
| Source | Serving | Zinc Content | % RDA (men 11 mg) |
|---|---|---|---|
| Oysters (cooked) | 3 oz (85 g) | 74 mg | 673% — by far the richest source |
| Beef (ground, cooked) | 3 oz | 5.4 mg | 49% |
| Crab (blue, cooked) | 3 oz | 3.2 mg | 29% |
| Pork loin (cooked) | 3 oz | 2.9 mg | 26% |
| Baked beans | ½ cup | 2.9 mg | 26% (phytate-inhibited; ~15–20% bioavailable) |
| Pumpkin seeds (roasted) | 1 oz (28 g) | 2.2 mg | 20% (phytate-inhibited) |
| Cashews | 1 oz | 1.6 mg | 15% (phytate-inhibited) |
| Yogurt (plain) | 8 oz | 1.7 mg | 15% |
RDA: Men ≥19 yrs: 11 mg/day; Women ≥19 yrs: 8 mg/day; Pregnant: 11 mg/day; Lactating: 12 mg/day. Tolerable Upper Limit (UL): 40 mg/day (chronic). Vegetarians/vegans may need 50% higher intakes due to phytate inhibition.
Clinical Evidence
| Trial / Evidence | Design | Key Result | GRADE |
|---|---|---|---|
| AREDS (Age-Related Eye Disease Study) Macular degeneration |
RCT; n=3,640; 10-year follow-up; zinc oxide 80 mg/day + antioxidants | Zinc + antioxidants → RR 0.72 (95% CI: 0.60–0.87) for progression to advanced AMD. AREDS2 formula retains zinc 80 mg/day as key component (with lutein/zeaxanthin replacing β-carotene). | High |
| Zinc Lozenges Meta-analysis Common cold (Science et al., CMAJ 2012) |
Systematic review & MA of RCTs | Zinc acetate lozenges ≥75 mg/day elemental zinc: ~33% ↓ cold duration (RR 0.67 for symptom resolution by day 7). Zinc sulfate: less consistent benefit. Bolus tablets (swallowed): no cold-treatment benefit. | Moderate |
| Zinc in Child Diarrhoea / Pneumonia (WHO/UNICEF evidence base) |
Multiple RCTs in deficient developing-country children | Zinc 10–20 mg/day for 2 weeks → ~25% ↓ acute diarrhoea duration; ↓pneumonia morbidity. WHO/UNICEF recommend zinc as adjunct treatment for acute diarrhoea in children <5 yrs. | Moderate |
| Growth in Zinc-Deficient Children (multiple RCTs) |
RCTs in stunted children (<−2 HAZ); 10–20 mg/day zinc supplementation | Significant improvements in height and weight velocity vs. placebo. Effect size largest in stunted children. Supports zinc deficiency as a primary cause of childhood stunting in low-income countries. | Moderate |
Evidence principle: Zinc's strongest RCT evidence is for AMD progression (AREDS, GRADE High) and childhood diarrhoea/pneumonia in deficient populations (WHO, Moderate). Oropharyngeal zinc lozenges for cold-duration reduction have moderate evidence but a strict requirement — lozenges must dissolve slowly in the mouth to release Zn²⁺ in the oropharynx; swallowed tablets do not work for this indication. Zinc supplementation in replete adults does not meaningfully improve immune function above baseline.
Deficiency & Excess
| Status | Signs & Symptoms | Lab Marker | Threshold |
|---|---|---|---|
| Deficiency | Hypogeusia/anosmia (gustin/CA-VI requires zinc); growth retardation; impaired wound healing; alopecia; dermatitis (perioral/perigenital in severe deficiency: acrodermatitis enteropathica); night blindness; ↑infection susceptibility; male hypogonadism | Plasma zinc (low sensitivity — falls late in deficiency); alkaline phosphatase (zinc-dependent); hair zinc; serum thymulin | Plasma zinc <70 µg/dL; clinical context essential as plasma zinc is insensitive |
| Adequate | Normal immune function, wound healing, taste sensation, growth | Dietary assessment; plasma zinc | RDA: 8–11 mg/day; UL 40 mg/day |
| Chronic excess (>40 mg/day UL) | Copper deficiency (zinc competes via MT induction; MT has higher Cu affinity → Cu trapped in shed enterocytes) → microcytic anaemia, peripheral neuropathy (myelopathy), neutropenia | Serum copper; ceruloplasmin; CBC | Therapeutic exception: 150–200 mg/day intentionally used in Wilson’s disease to block Cu absorption via MT mechanism |
| Acute high dose (>150–200 mg) | Nausea, vomiting, abdominal cramping (direct GI irritant effect of ionic zinc) | Clinical | Self-limiting; no long-term harm from single episode |
Connections
References
- Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009;12(6):646-52. doi:10.1097/MCO.0b013e3283312956 · PubMed 19770647
- Science M, Johnstone J, Roth DE, Guyatt G, Loeb M. Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials. CMAJ. 2012;184(10):E551-61. doi:10.1503/cmaj.111990 · PubMed 22566526
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-36. doi:10.1001/archopht.119.10.1417
- Berg JM, Tymoczko JL, Stryer L. Biochemistry. 9th ed. W.H. Freeman; 2019. Chapter on zinc enzymes and metalloenzymes.
- Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th ed. Elsevier; 2021. Chapter on trace minerals.